July 28, 2026 · NeurologyLive
Immunobrain
IBC-Ab002: an established molecular target. Different therapeutic approach.
Distinct cellular responses. Specifically engineered antibody. Unique mechanism of action. Intermittent dosing regimen.
Advancing a clinical approach to treating Alzheimer’s as a systemic disease
0
Years of dogma-breaking research
0+
Peer-reviewedpublications
0
Grantedpatents
Growing Challenge
NEARLY 10 MILLION
new cases of dementia every year worldwide
As the world's population ages, Alzheimer's disease and other dementias are becoming increasingly prevalent.
Our Mission
Longer lives to come with healthier brains
Immunobrain is on a mission to bring a differentiated approach, driving neuroprotective effect, with convenient quarterly dosing and the potential to significantly slow - or prevent - cognitive decline.
PipelineLatest News
July 14, 2026 · PR Newswire
Immunobrain Announces Nature Medicine Publication and Late-Breaking AAIC 2026 Presentation for IBC-Ab002 in Early Alzheimer’s Disease
Read full postMarch 12, 2026 · PR Newswire